MCO-010
Phase 2- Indications
- Retinitis pigmentosa
Company intelligence / Profile preview
Nanoscope Technologies develops biomedical technologies including diagnostics and therapeutic devices/molecules focused primarily on ocular diseases. Its proprietary gene delivery platforms target inherited retinal degenerative conditions using ambient light-sensitive opsins. The company has filed patents in molecular biology, biotechnology, gene delivery for eye diseases, medical imaging, and transcription factors. It has received grant funding from NIH/NINDS/NEI.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nanoscope Technologies.